Journal
DRUG DISCOVERY TODAY
Volume 25, Issue 8, Pages 1528-1534Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2020.06.013
Keywords
-
Categories
Funding
- Campania Region, Scientific Research Department, POR-FESR [B61C17000070007 (OR3)]
Ask authors/readers for more resources
Here, we highlight recent findings on the urokinase plasminogen activator (uPA)/uPA receptor (uPAR) system that suggest its potential role as a main orchestrator of fatal progression to pulmonary, kidney, and heart failure in patients with coronavirus. Patients with prolonged background inflammation can present aberrant inflammatory reactions, well recognized as the main factors that can result in death and probably sustained by a dysregulated uPA/uPAR system. SuPAR, the soluble form of uPAR, represents a biomarker of disease progression, and its levels correlate well with comorbidities associated with the death of patients with coronavirus. New drugs that regulate the uPA/uPAR system could help treat the severe complications of highly pathogenic human coronaviruses (hCoVs), including pandemic coronavirus 2019 (COVID-19).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available